XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Total revenue, net $ 306,911 $ 369,193 $ 583,187
Less: Cost of goods sold 102,142 108,631 121,327
Less: Cost of goods sold - restructuring inventory 39,228 18,078  
Gross margin 165,541 242,484 461,860
Operating expenses:      
Selling, general and administrative 199,938 304,416 408,334
Research and development 22,219 30,411 29,307
Restructuring 10,972 13,526 13,717
Total operating expenses 233,129 348,353 451,358
Operating (loss) income (67,588) (105,869) 10,502
Interest income 11,863 2,819 1,220
Interest expense (8) (15) (129)
Other income (expense), net 2,063 (740) (302)
(Loss) income from operations before taxes (53,670) (103,805) 11,291
Provision for income taxes (5,442) (1,998) (3,562)
Net (loss) income $ (59,112) $ (105,803) $ 7,729
(Loss) earnings per share:      
Basic [1] $ (0.15) $ (0.26) $ 0.02
Diluted [1] $ (0.15) $ (0.26) $ 0.02
Weighted average shares outstanding:      
Basic 407,655 401,155 395,992
Diluted 407,655 401,155 402,480
Product Revenue, Net      
Total revenue, net $ 285,299 $ 366,511 $ 580,320
Licensing and Royalty Revenue      
Total revenue, net $ 21,612 $ 2,682 $ 2,867
[1] Excluding the licensing revenue change in estimate and Medicaid change in estimate, both discussed in Note 12 – Revenue Recognition, net loss per share basic and diluted for the year ended December 31, 2023 would have been $(0.21).